However, the emerging role of immunoproteasome involvement in autoantigen presentation as well as the ability of BTZ to inhibit the activation of NF-κB and suppress the release of pro-inflammatory cytokines, including IL-6, have increased interest in exploring the therapeutic potential of proteasome inhibitors in inflammatory and autoimmune disease settings (35). The gene discussed is IL6; the disease is autoimmune disease.